Expiring Patents, Aspiring Generics
Big Pharma is headed for a big change. And generics are getting ready to grab their share. Branded drugs with sales of $86 billion would lose patent protection during 2013 to 2017. Some of the most lucrative targets for generics in 2013 include Eli Lilly’s Cymbalta, Biogen Idec’s Avonex and Merck KGaA's Rebif. These drugs generated global sales worth $10 billion in 2012.
Generic drugs, once available, are typically 30% to 80% cheaper than the brand names, and can capture 80% of the market within the first year. Which means the next few years hold an unprecedented growth opportunity for the generic drug industry. And that has investors feeling feverish.
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for just $9.95.
With this Motif, you can buy the following basket of stocks for just $9.95:
||Segment & Stocks
||1 MO / 1 YR Return
Quotes delayed 15 mins. Currently Jun 28, 2016 5:30:18 AM. Fields are marked with -- when data is unavailable.